In a New York Times op-ed on April 28, Michael T. Osterholm and Mark Olshaker analyze the challenges of diagnostic testing for COVID-19, including the potential for false negatives, the fact that individuals would need to be screened repeatedly, and accuracy issues. They also warn of problems with antibody testing. They recommend testing improvements, including greater FDA oversight, increased production of testing reagents and equipment, and intensified “syndromic surveillance.” Prof. Osterholm is Director of CIDRAP, a Consortium member center. Read the full article here.
Tuesday, April 28, 2020